HOSPITAL UNIVERSITARIO RUBER
Departamento
Université Libre de Bruxelles
Bruselas, BélgicaPublicaciones en colaboración con investigadores/as de Université Libre de Bruxelles (14)
2024
-
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)
Radiotherapy and Oncology
-
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83
2023
-
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
European Journal of Cancer, Vol. 178, pp. 23-33
-
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2998-3008
-
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2988-2997
-
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis
Radiotherapy and Oncology, Vol. 186
2022
-
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
npj Breast Cancer, Vol. 8, Núm. 1
2021
-
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆
Annals of Oncology, Vol. 32, Núm. 12, pp. 1475-1495
-
Sacituzumab govitecan in metastatic triple-negative breast cancer
New England Journal of Medicine, Vol. 384, Núm. 16, pp. 1529-1541
2020
-
Beta-blocker effect on ST-segment: A prespecified analysis of the EARLY-BAMI randomised trial
Open Heart, Vol. 7, Núm. 2
-
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer
ESMO Open, Vol. 5
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
-
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
British Journal of Cancer
2016
-
Handbook of HER2-targeted agents in breast cancer
Springer International Publishing, pp. 1-110